Clinical Trial Results:
A Phase 2, Open-Label, Single Dose Level, 24-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients with Fabry Disease
Summary
|
|
EudraCT number |
2005-004384-33 |
Trial protocol |
GB |
Global completion date |
12 Mar 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1 |
This version publication date |
15 Sep 2016
|
First version publication date |
15 Sep 2016
|
Other versions |
v2 |
Summary report(s) |
FAB-CL-203 synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.